Shape Therapeutics

Shape Therapeutics Inc. is a biotechnology company based in Seattle, Washington, focused on developing programmable RNA medicines through advanced AI-driven genomic technologies. Founded in 2018, the company aims to create transformative gene therapies that address the genetic causes of diseases by utilizing RNA editing techniques instead of permanent DNA modification. The company’s technology suite includes several proprietary platforms, such as RNAfix®, which enables precise RNA editing, and AAVid™, a next-generation delivery system optimized for targeting the central nervous system. Shape Therapeutics is also developing gene therapies for conditions like Parkinson’s disease and ABCA4-driven diseases, offering innovative solutions for genetic disorders that are challenging to treat with traditional methods. With significant funding and a team of experts in bioengineering and genetics, Shape Therapeutics is positioned as a leader in the RNA-based gene therapy field.